BRIEF — Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Oct 13 (Reuters) — NovaBridge Biosciences: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis Visara: Secures Exclusive Worldwide Rights To Develop And Commercialize Ht006.2.2 Excluding Greater China Visara: Enters Exclusive License Ag